Logo

Novartis' Cosentyx (secukinumab) Receives the US FDA's Approval for the Treatment of Moderate to Severe Plaque Psoriasis

Share this

Novartis' Cosentyx (secukinumab) Receives the US FDA's Approval for the Treatment of Moderate to Severe Plaque Psoriasis

Shots:

  • The approval is based on two P-III studies evaluating Cosentyx (75 mg/ 150 mg) vs PBO in children aged 6 to <18 yrs with plaque psoriasis
  • The first study demonstrates reduction in psoriasis severity @12 wks.- PASI 75 response for 75mg and 150mg (55%- 86% vs 10%- 19%)- achieved clear or almost clear skin response (32% - 81% vs 5%- 5%) . The safety profile in both trials was consistent with the safety profile and no new safety signals were identified
  • The therapy marks the first FDA approval in a pediatric population in the US and clinical profile is supported by 5 ys of clinical data in adults that showed long-term safety and efficacy across PsO- PsA- and AS

  Ref: PRNewswire | Image: Novartis

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions